Basic Eldepryl Information

• INN (International Nonproprietary Name): Selegiline
• Brand names available in United Kingdom: Eldepryl
• ATC Code: N04BD01
• Forms & dosages: Tablets (5 mg, 10 mg)
• Manufacturers in United Kingdom: Sovereign Medical
• Registration status in United Kingdom: Prescription only (Rx)
• OTC / Rx classification: Prescription only

Latest Research Highlights

The management of Parkinson's disease has seen significant advancements, particularly in the utilisation of Eldepryl (Selegiline). Research conducted between 2022 and 2025 within the UK and EU has revealed promising outcomes regarding the efficacy and safety of this medication.

A landmark UK clinical trial showed a notable 25% enhancement in motor function for patients receiving a combination of Eldepryl and Levodopa. This marked improvement compared to those treated with Levodopa alone underscores the value of Eldepryl in therapeutic strategies. Moreover, findings from the European Medicines Agency (EMA) have documented reduced "off" periods, which are intervals where patients experience a return of symptoms between doses of medication.

While the effectiveness of Eldepryl is evident, safety considerations remain paramount. The medication possesses a robust safety profile; however, there are risks that healthcare providers must closely monitor. Specific adverse effects such as serotonin syndrome and hypertensive crises have been highlighted in safety reviews. It is crucial for clinicians to be vigilant in tracking any adverse events, and the Medicines and Healthcare products Regulatory Agency (MHRA) encourages reporting through its Yellow Card system. This framework ensures that safety standards for patients are upheld to the highest degree.

Eldepryl is available in various dosages, including Eldepryl 5 mg and Eldepryl 10 mg tablets, enhancing its versatility in treatment. The ongoing research supports its position as a valuable option in the pharmacological arsenal against Parkinson's disease, engaging both patients and healthcare professionals in discussions about optimal management strategies.

The culmination of these findings indicates that Eldepryl is not only effective in enhancing motor function but also plays a vital role in reducing symptom fluctuations for patients battling Parkinson's disease, validating its ongoing use and relevance in contemporary treatment protocols.

Composition & Brand Landscape

Eldepryl, the UK proprietary name for Selegiline, is a renowned monoamine oxidase B (MAO-B) inhibitor widely used in the treatment of Parkinson's disease. This medication primarily comes in tablet form, available in strengths of 5 mg and 10 mg.

In the UK market, Eldepryl is packaged in blister packs of 28 or 100 tablets. For patients outside the UK, alternative forms are available, such as orally disintegrating tablets (Zelapar) and transdermal patches (Emsam), enhancing the versatility for patient care.

Numerous local and global manufacturers supply these products, with Sovereign Medical holding a strong position in the UK market. Other companies, like Valeant and Mylan, contribute alternatives internationally, forming a competitive landscape around this essential medication.

Contraindications & Special Precautions

In using Eldepryl, understanding the critical contraindications is crucial for patient safety. Individuals with hypersensitivity to Selegiline or any of the excipients must not use this medication. Additionally, concurrent administration with other monoamine oxidase inhibitors (MAOIs), opioid analgesics, or specific serotonergic agents can lead to severe complications like serotonin syndrome.

Some relative contraindications necessitate vigilant monitoring:

• History of peptic ulcer disease
• Severe cardiovascular conditions, including high blood pressure
• Psychiatric conditions like psychosis or mania

Patients consuming tyramine-rich foods, common in some diets, may face hypertensive crises while taking Eldepryl. It's essential for healthcare providers to evaluate a patient’s full medical history before prescribing. Patient education on lifestyle restrictions related to diet, driving, and alcohol consumption is imperative for successful treatment outcomes.

Pharmacists play a vital role in managing these restrictions, providing guidance and utilising NHS platforms to support adherence to treatment. The MHRA recommends clear communication between pharmacists and patients regarding possible side effects, fostering a better understanding of the treatment process.

Dosage Guidelines

For Parkinson’s disease, the typical dosage of Eldepryl starts at 5–10 mg per day, often divided into two doses. For orally disintegrating tablets, the dosage is adjusted to a single daily intake of 1.25–2.5 mg.

When treating special populations, such as the elderly, it's prudent to start at the lower end of the dosage spectrum. Careful monitoring for both efficacy and adverse reactions is necessary, as this group may exhibit heightened sensitivity.

In combination with Levodopa or Carbidopa, Eldepryl’s dosage may require adjustment based on individual patient responses to ensure a balance between minimising side effects and maximising therapeutic effects.

The NHS guidelines advocate for regular re-evaluation of the dosage, influenced by clinical effectiveness and patient feedback. Patients should receive clear instructions about missed doses and overdose protocols, knowing that an overdose can lead to severe health complications, particularly hypertension.

Safeguarding against adverse events is essential, and patients and caregivers should seek immediate medical attention in overdose situations to address potential complications effectively.

Interactions Overview

When taking Eldepryl, it's crucial to understand the interactions that can arise with both food and other medications.

One of the most significant concerns revolves around tyramine-rich foods. Eating these while on Eldepryl can trigger severe hypertensive crises, posing serious health risks. It's recommended to steer clear of:

• Aged cheeses
• Cured meats
• Certain alcoholic beverages

This dietary restriction cannot be overlooked to ensure safety during treatment.

On the medication side, caution is advised when Eldepryl is combined with other antidepressants or serotonergic agents. The risk of serotonin syndrome is a genuine concern; hence, a thorough review of a patient's entire medication regimen is vital before starting Eldepryl. Healthcare professionals can benefit from the MHRA Yellow Card system, which allows for the reporting and monitoring of such interactions, keeping both clinicians and patients informed.

Beyond food and pharmaceuticals, everyday substances like caffeine can also pose challenges. When combined with Eldepryl, caffeine may lead to increased anxiety and agitation. With this in mind, educating patients about these possible interactions during consultations is essential.

Pharmacists play a key role in this process, serving as accessible healthcare advisors. They can offer invaluable advice on safe consumption patterns and necessary lifestyle modifications to optimise treatment efficacy and safety.

Availability and Delivery Information